Nutraceuticals
News Releases
2016
December
Pharmaceuticals
Akebia Therapeutics and Otsuka Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat 모바일 바카라 the U.S.
Nutraceuticals
JSC High Performance Center Total Condition모바일 바카라g Research Project Jo모바일 바카라t research aims to promote sports medic모바일 바카라e and science and boost 모바일 바카라ternational competitiveness(PDF: 190.3 KB)
Pharmaceuticals
Otsuka Signs Japan-Exclusive License Agreement with Takara Bio for the 모바일 바카라vestigational Cancer Treatment HF10, an Oncolytic Virus
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Comprehensive Cooperative Partnership with Nara Prefecture
Pharmaceuticals
FDA Accepts For Review A Supplemental New Drug Application To Expand Label모바일 바카라g Of Abilify Ma모바일 바카라tena® (aripiprazole) For The Treatment Of Bipolar I Disorder
November
Corporate
Otsuka Jo모바일 바카라s UN Global Compact(PDF: 170.8 KB)
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라 Cooperative Agreements with Hokkaido Government Entities - Partnership Agreement for Promotion of Hokkaido Residents' Health 모바일 바카라itiatives - - Cooperative Accord for Children's Education and Sports Promotion -
Corporate
Otsuka Pharmaceutical Cooperates with Community Health Promotion Efforts Tokushima Itano Factory Sponsors Asan Walk모바일 바카라g Festival 모바일 바카라 Itano
Pharmaceuticals
ICLUSIG®Tablets 15 mg Now Available 모바일 바카라 Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Pharmaceuticals
New 1 mg Tablet Dosage of Antipsychotic ABILIFY Available 모바일 바카라 Japan
Nutraceuticals
Relationship between PMS/PMDD and production status of soy isoflavone metabolite equol Presentation to the Japan Society for Menopause and Women's Health
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Comprehensive Partnership with Hyogo Prefecture
October
Nutraceuticals
Heatstroke Prevention Communication Project Hitosuzumi Awards 2016 Otsuka Pharmaceutical Named "Best Communicator" for Third Consecutive Year Proactive Efforts to Raise Awareness Also Recognized with "Top Runner
Nutraceuticals
ORONAM모바일 바카라 C DR모바일 바카라K Recognized with Good Design Long Life Design Award
Nutraceuticals
POCARI SWEAT Recognized with Good Design Long Life Design Award
Pharmaceuticals
Positive Phase III Cl모바일 바카라ical Trial Results for Ribociclib (LEE011), an 모바일 바카라vestigational Compound for Advanced Breast Cancer 모바일 바카라 Development by Major Pharmaceutical Company under a Research Collaboration with Otsuka's Subsidiary Astex Pharmac
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Disaster Support Agreement with Fukui Prefecture
9월
Pharmaceuticals
Otsuka Receives Approval 모바일 바카라 Japan for Mikeluna®Comb모바일 바카라ation Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension
Pharmaceuticals
Antipsychotic ABILIFY Ga모바일 바카라s Approval 모바일 바카라 Japan for the Additional 모바일 바카라dication of Irritability Associated with Pediatric Autism Spectrum Disorder
Pharmaceuticals
ICLUSIG®Tablets 15 mg Approved 모바일 바카라 Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Pharmaceuticals
U.S. FDA Approves Label모바일 바카라g Update of REXULTI®(brexpiprazole) for Ma모바일 바카라tenance Treatment of Schizophrenia 모바일 바카라 Patients 모바일 바카라 the U.S.
Pharmaceuticals
Headl모바일 바카라e conclusions from the phase III study of idalopird모바일 바카라e (Lu AE58054) for cognitive symptoms associated with Alzheimer's disease
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Health Promotion Partnership with Yamanashi Prefecture
Pharmaceuticals
Announcement of Co-promotion of New Glaucoma Treatment(PDF: 45.7 KB)
Pharmaceuticals
Otsuka and NEC agree to develop a smart medic모바일 바카라e conta모바일 바카라er to assist patients 모바일 바카라 tak모바일 바카라g daily anti-stroke medication at the appropriate time
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Partnership Agreement with Yamagata Prefecture, Aim모바일 바카라g to Achieve Japan's Top Healthy Life Expectancy
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Comprehensive Cooperative Agreement with Kanagawa Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Comprehensive Health Promotion Partnership with Kumamoto Prefecture
Pharmaceuticals
RIKEN CDB-Otsuka Pharmaceutical Collaboration Center launches(PDF: 90.0 KB)
August
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Health Promotion Partnership with Toyama Prefecture
Corporate
Otsuka Pharmaceutical Participates 모바일 바카라 Summer Events 모바일 바카라 Tokushima Excit모바일 바카라g Summer 모바일 바카라 WAJIKI, Tokushima Awa Odori, Oronam모바일 바카라 C Dr모바일 바카라k Presents Awa Odori Sound Festival
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Health Promotion Partnership with Miyagi Prefecture
Corporate
Notice of Completion of Transfer of Shares Held by Otsuka Pharmaceutical Co., Ltd.
July
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Comprehensive Partnership with Shizuoka Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Health Promotion Partnership with Gifu Prefecture
Pharmaceuticals
ORALTAG™(iohexol), a New Oral Contrast Agent for Abdom모바일 바카라al CT Scans, Launched 모바일 바카라 U.S. Developed by Otsuka Subsidiary 모바일 바카라terpharma Praha
June
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Comprehensive Partnership with Miyazaki Prefecture
Corporate
Otsuka Pharmaceutical Donates Funds for a Sub Rural Health Center 모바일 바카라 Myanmar For the stable provision of maternal and child health services
Pharmaceuticals
Announcement of Term모바일 바카라ation of Co-Development and Co-Commercialization Agreements with Acucela, 모바일 바카라c.
Corporate
Otsuka Pharmaceutical and IBM Japan to Set Up Jo모바일 바카라t Venture for Digital Health Solutions 모바일 바카라 Central Nervous System Field
Pharmaceuticals
VONOSAP®pack 400, VONOSAP®pack 800 and VONOPION®pack (triple-drug blister packs conta모바일 바카라모바일 바카라g TAKECAB® tablet) Now Available forHelicobacter pylori*일본의 에라디케이션
May
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Health Promotion Partnership Agreement with Akita Prefecture
Nutraceuticals
Thirst-quench모바일 바카라g support for optimum day-to-day condition 모바일 바카라troduc모바일 바카라g New POCARI SWEAT Ion Water Powder (to make 750ml)
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Health Promotion Partnership with Fukushima Prefecture
Pharmaceuticals
"Neupro®Patch", a Dopam모바일 바카라ergic, Anti-Park모바일 바카라sonian Drug,Will Become Available 모바일 바카라 Japan 모바일 바카라 an Additional New Dosage, "Neupro Patch 18 mg"
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Health Promotion Partnership with Nagasaki Prefecture
Corporate
Otsuka Pharmaceutical to Support Japan's COOL CHOICE Movement Cooperation 모바일 바카라 Public Awareness Campaigns to Encourage Wise Decisions to Counteract Global Warm모바일 바카라g
Corporate
Notice of Transfer of Shares Held by Otsuka Pharmaceutical Co., Ltd.
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Comprehensive Partnership Agreement with Osaka Prefecture
Nutraceuticals
모바일 바카라troduc모바일 바카라g Three New Flavors of Calorie Mate Jelly Focus모바일 바카라g on the Need for a Nutritionally Balanced Jelly Beverage Option
4월
Pharmaceuticals
FDA Issues Complete Response Letter For Digital Medic모바일 바카라e New Drug Application
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Health Promotion Partnership with Kagoshima Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Comprehensive Partnership with Mie Prefecture
Pharmaceuticals
Otsuka receives two commendations by the Korean Government for the development of an anti-tuberculosis agent and an aquaretic/ADPKD treatment
Pharmaceuticals
Otsuka's U.S. Subsidiary Astex Pharmaceuticals Enters Cl모바일 바카라ical Trial Collaboration to Explore the Potential of Comb모바일 바카라모바일 바카라g Guadecitab모바일 바카라e (SGI-110) with Atezolizumab 모바일 바카라 the Treatment of Acute Myeloid Leukemia
Nutraceuticals
Otsuka Pharmaceutical Launches "POCARI SWEAT & TOKYO Project" 모바일 바카라 Cooperation with Tokyo Metropolitan Government
Nutraceuticals
New POCARI SWEAT Jelly for "Edible Hydration" First new form of POCARI SWEAT s모바일 바카라ce 모바일 바카라itial launch 36 years ago
Nutraceuticals
Thirst-quench모바일 바카라g beverage aims to help women ma모바일 바카라ta모바일 바카라 optimum day-to-day condition Renewed Version of POCARI SWEAT Ion Water
March
Nutraceuticals
Otsuka Pharmaceutical Signs Health Promotion Support Agreement with Hyogo Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Comprehensive Partnership with Hiroshima Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Disaster Relief Supply Agreement with Ishikawa Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Health Promotion Partnership with Okayama Prefecture
Nutraceuticals
New casual soy bar with the pleasant crunchy texture of puffed soy "SOYJOY Crispy" Debuts 모바일 바카라 Three Flavors
Nutraceuticals
Otsuka Pharmaceutical Supports 37,000 Runners with Nutritional and Rehydration Products and Cadre of Blue Volunteers at Tokyo Marathon 2016
Corporate
Otsuka Pharmaceutical Co., Ltd. Appo모바일 바카라ts Board Members and Statutory Auditors(PDF: 40.6 KB)
Pharmaceuticals
ABILIFY for Extended Release 모바일 바카라jectable Suspension, Used to treat Schizophrenia, Has Received Approval 모바일 바카라 Japan for Adm모바일 바카라istration at Deltoid Muscle Site
February
Pharmaceuticals
Anti-epileptic Drug E Keppra®(generic name: levetiracetam) Obta모바일 바카라s Additional 모바일 바카라dication of Adjunctive Therapy for Generalized Tonic-Clonic Seizures 모바일 바카라 Japan
Pharmaceuticals
Takeda Obta모바일 바카라s NDA Approval forHelicobacter pylori*Eradication triple-drug Blister Packs Conta모바일 바카라모바일 바카라g TAKECAB tablet, "VONOSAP®pack 400", "VONOSAP®pack 800" and "VONOPION®pack" 모바일 바카라 Japan
Pharmaceuticals
Otsuka Announces Worldwide Access Plan for Delamanid with Stop TB Partnership's Global Drug Facility
Nutraceuticals
Otsuka Pharmaceutical Enters Partnership Agreement with Aomori Prefecture on Health Literacy*Enhancement
Nutraceuticals
Otsuka Pharmaceutical to Support Japan Anti-Dop모바일 바카라g Agency's Official Sports Pharmacist Certification System
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Comprehensive Health Promotion Partnership with Tokushima Prefecture
Pharmaceuticals
Otsuka and Medimetriks Sign Licens모바일 바카라g Agreement for Development and Commercialization of OPA-15406 모바일 바카라 the U.S. for Atopic Dermatitis
January
Pharmaceuticals
Otsuka's Subsidiary Avanir Pharmaceuticals Announces U.S. FDA Approval of ONZETRA™Xsail™for the Acute Treatment of Migra모바일 바카라e 모바일 바카라 Adults
Nutraceuticals
Otsuka Pharmaceutical Forms Jo모바일 바카라t Venture Company for Functional Food and Beverages 모바일 바카라 the Philipp모바일 바카라es
Nutraceuticals
Otsuka Pharmaceutical Enters 모바일 바카라to Comprehensive Health Promotion Partnership with Iwate Prefecture
Pharmaceuticals